Fig. 9

Bisp-AFN induces a shift from naive and dysfunctional T cells towards effector and reprogrammable CTLs. A Schematic representation of the experiment. B Flow cytometry gating strategy to determine CD8⁺ T cells: CD45⁺ living cells, TCR-β⁺ T cells, CD8⁺CD4⁻ T cells. Contour plots show the shift in expression of the indicated markers and cell populations over the different treatments. C, D Draining LN (C) and B16 tumors (D) were analyzed for CD44 and CD62L expression on CD8⁺ T cells. Naive cells were identified as CD44^lowCD62L^high, effector T cells as CD44^highCD62L^low and effector-memory T cells in draining LN as CD44^highCD62L^high. E CD8⁺ T cells in B16 tumors were analyzed for CD38 and CD101 expression with dysfunctional T cells described as CD38⁺CD101⁺ and reprogrammable, plastic T cells as CD38⁻CD101⁻. Results show bar charts of individual values with mean ± SEM. Data obtained upon administration of PBS are represented in grey while data obtained after Clec9A-PDL1-AFN administration are visualized in green. Shown is one representative experiment. Graphs were analyzed using unpaired parametric t-test (draining LN naive T cells, tumor effector T cells, tumor dysfunctional and reprogrammable T cells) or unpaired nonparametric Mann–Whitney t-test (draining LN effector T cells, draining LN memory T cells, tumor naive T cells). * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001